Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;27(46):2200845.
doi: 10.2807/1560-7917.ES.2022.27.46.2200845.

Large increase in bloodstream infections with carbapenem-resistant Acinetobacter species during the first 2 years of the COVID-19 pandemic, EU/EEA, 2020 and 2021

Pete Kinross  1   2 , Carlo Gagliotti  3   2 , Hanna Merk  1 , Diamantis Plachouras  1 , Dominique L Monnet  1 , Liselotte Diaz Högberg  1 ; EARS-Net Study Group  4 ; EARS-Net Study Group participants
Collaborators, Affiliations

Large increase in bloodstream infections with carbapenem-resistant Acinetobacter species during the first 2 years of the COVID-19 pandemic, EU/EEA, 2020 and 2021

Pete Kinross et al. Euro Surveill. 2022 Nov.

Abstract

Recent data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) show a large increase of +57% in Acinetobacter species bloodstream infections in the European Union and European Economic Area in the first years of the COVID-19 pandemic (2020-2021) compared with 2018-2019. Most were resistant to carbapenems, from intensive care units, and in countries with ≥ 50% carbapenem resistance in Acinetobacter spp. in 2018-2019. This highlights the requirement for reinforced Acinetobacter preparedness and infection prevention and control in Europe.

Keywords: Acinetobacter; COVID-19; EU/EEA; bacteraemia; pandemic.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Acinetobacter species bloodstream infections reported by laboratories that continuously reported data to EARS-Net, by carbapenem susceptibility testing result and type of patient ward, EU/EEA, 2017–2021 (n = 16,626)
Figure 2
Figure 2
Bloodstream infections with carbapenem-resistant Acinetobacter species, reported by laboratories that continuously reported data to EARS-Net, by country groupa and year, EU/EEA, 2017–2021 (n = 9,542)
Figure 3
Figure 3
Percentage and number of bloodstream infections with carbapenem-resistant Acinetobacter species from laboratories that continuously reported data to EARS-Net, by country groupa , EU/EEA, 2018–2019 vs 2020–2021 (n = 9,542)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: Carbapenem-resistant Acinetobacter baumannii in healthcare settings – 8 December 2016. Stockholm: ECDC, 2016 Available from: https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-ca...
    1. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual epidemiological report for 2021. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-...
    1. European Centre for Disease Prevention and Control (ECDC). TESSy – The European Surveillance System – antimicrobial resistance (AMR) reporting protocol 2022 – European Antimicrobial Resistance Surveillance Network (EARS-Net) surveillance data for 2021. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/ears-net-reporting-proto...
    1. European Centre for Disease Prevention and Control (ECDC). Surveillance atlas of infectious diseases. Stockholm: ECDC; 2022. Date accessed: 25 October 2022. Available from: https://www.ecdc.europa.eu/en/surveillance-atlas-infectious-diseases
    1. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-55. 10.1016/S0140-6736(21)02724-0 - DOI - PMC - PubMed